Marco Rubatto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7997899/publications.pdf

Version: 2024-02-01

19 papers	273 citations	933447 10 h-index	940533 16 g-index
20 all docs	20 docs citations	20 times ranked	189 citing authors

#	Article	IF	Citations
1	Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?. Journal of Dermatological Treatment, 2022, 33, 2495-2502.	2.2	19
2	SÃ©zary Syndrome: Different Erythroderma Morphological Features with Proposal for a Clinical Score System. Cells, 2022, 11, 333.	4.1	1
3	Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficultâ€toâ€treat population. British Journal of Dermatology, 2022, 187, 263-265.	1.5	16
4	Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatologic Therapy, 2022, 35, e15378.	1.7	20
5	Realâ€life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	16
6	Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study. Dermatologic Therapy, 2022, 35, e15492.	1.7	3
7	Extensive â€œhalo naeviâ€•phenomenon and regression of melanin during nivolumab treatment in metastatic melanoma: A predictor of a better outcome?. Dermatologic Therapy, 2022, 35, e15559.	1.7	1
8	Switching from <scp>IL23</scp> inhibitors to <scp>IL17</scp> inhibitors: A safe and effective practice?. Dermatologic Therapy, 2022, 35, .	1.7	6
9	Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or SÃ©zary Syndrome. Journal of Investigative Dermatology, 2021, 141, 484-495.	0.7	31
10	Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit. Future Oncology, 2021, 17, 759-761.	2.4	5
11	Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications. International Journal of Molecular Sciences, 2021, 22, 4561.	4.1	21
12	Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review. Oncotarget, 2021, 12, 1116-1121.	1.8	9
13	The Effect of the COVID-19 Lockdown on Melanoma Diagnosis in Italy. Clinics in Dermatology, 2021, 39, 911-919.	1.6	28
14	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. European Journal of Cancer, 2021, 157, 250-258.	2.8	52
15	Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma. Journal of Clinical Medicine, 2021, 10, 4994.	2.4	4
16	Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials. Journal of Clinical Medicine, 2021, 10, 5475.	2.4	8
17	Melanoma Management during the COVID-19 Pandemic Emergency: A Literature Review and Single-Center Experience. Cancers, 2021, 13, 6071.	3.7	11
18	Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19. Seminars in Oncology, 2020, 47, 302-304.	2.2	15

#	Article	IF	Citations
19	Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097700.	3.2	6